As viral diseases continue to present complex global health challenges, scientists are increasingly focusing on therapies that target host-cell mechanisms used by viruses to replicate. Reflecting this emerging scientific direction, Godavari Biorefineries Limited secured a patent from the Japan Patent Office (JPO) for its invention titled “Use of Compounds for Treating Viral Infections.” The patent protects the second medical use of the company’s lead compound MSP22 and its derivatives for antiviral applications through the inhibition of Vacuolar ATPase (V-ATPase), a key cellular mechanism associated with viral infection pathways.
Targeting Host-Cell Mechanisms to Combat Viral Infections
Unlike conventional antiviral drugs that directly target viruses, the newly patented compounds work by inhibiting V-ATPase activity within host cells. The cellular enzyme complex plays a critical role in viral entry and replication. By targeting this pathway, the compounds may disrupt the environment viruses require to multiply, potentially offering a broader antiviral strategy that could be effective against multiple viral families rather than a single virus type. This innovation forms part of Godavari Biorefineries’ expanding life sciences research programme, aimed at developing advanced therapeutic solutions for global health challenges.
Collaborative Research Driving Pharmaceutical Innovation
The antiviral compounds were developed through the company’s biotechnology initiative Sathgen Therapeutics, which focuses on translating scientific discoveries into therapeutic applications. The patent recognises the collaborative efforts of the research team, including Dr. Maithili Athavale, Dr. Sandip Gavade, Dr. Prashant Kharkar, and Dr. Sangeeta Srivastava, who are listed as inventors. Their work represents a significant step in building a strong intellectual property portfolio in antiviral drug discovery, reinforcing the company’s growing presence in pharmaceutical innovation.
Strengthening Global Intellectual Property Protection
Securing the patent in Japan marks an important milestone in Godavari Biorefineries’ strategy to protect its antiviral technology in major global markets. Samir Somaiya, Chairman and Managing Director of Godavari Biorefineries Limited, said, “Securing this patent in Japan reflects a natural extension of our ongoing work in drug discovery. As we advanced our R&D efforts on lead molecules, we identified their potential to inhibit mechanisms such as V-ATPase, which are relevant in antiviral applications. Protecting this therapeutic use in a market like Japan is an important step in strengthening our intellectual property portfolio and advancing molecules with broader clinical potential.”
Exploring New Directions in Antiviral Therapy
Researchers believe that targeting V-ATPase, a critical cellular enzyme exploited by viruses, could open new avenues in antiviral treatment. Dr. Sangeeta Srivastava, Executive Director at Godavari Biorefineries Limited, stated, “Research that targets V-ATPase, a critical cellular enzyme complex exploited by viruses, could open new directions in antiviral therapy. This patent reflects our effort to translate scientific research into therapeutic approaches that could eventually address critical global health challenges.”
Expanding Life Sciences Through Sathgen Therapeutics
Godavari Biorefineries is advancing its life sciences strategy through Sathgen Therapeutics, its clinical-stage biotechnology arm. The initiative is developing a pipeline of novel cancer and antiviral therapies, building on the company’s research in host-cell biological pathways and anti-cancer molecules. Furthermore, the programme is supported by international research collaborations, reinforcing the company’s commitment to transforming scientific discovery into practical therapeutic solutions. As per the press release, through these efforts, Godavari Biorefineries continues to strengthen its role in life sciences innovation, antiviral drug research, and global pharmaceutical development.
